XM does not provide services to residents of the United States of America.

Indian shares rise ahead of cenbank decision



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares rise ahead of cenbank decision</title></head><body>

Updates at 9:44 a.m. IST

By Bharath Rajeswaran

Oct 9 (Reuters) -Indian shares rose on Wednesday, led by information technology and pharma stocks, ahead of the monetary policy decision amid expectations the central bank will continue to hold interest rates.

The Nifty 50 index .NSEI was up 0.25% at 25,073 points as of 9:44 a.m. IST, while the S&P BSE Sensex .BSESN added 0.18% to 81,778.84.

The Reserve Bank of India (RBI) is expected to keep the key policy rates unchanged for a tenth consecutive meeting as it aims to keep inflation at target, but the central bank's hawkish 'withdrawal of accommodation' policy stance and comments will be under scrutiny.

The policy decision is due at 10:00 a.m. IST.

Any dovish commentary on the economy or rates will aid momentum in domestic equities, especially in rate-sensitive sectors such as real estate, auto and banking, analysts said.

India's benchmark indexes snapped a six-session losing streak on Tuesday, as investors bought the dip, while better-than-expected results for the ruling party in a state assembly election also supported sentiment.

The ruling Bharatiya Janata Party's victory in Haryana has come as a confidence booster for markets, VK Vijayakumar, chief investment strategist at Geojit Financial Services said.

"The sentiments will get a further lift if the RBI decides to change stance to neutral and sound a bit dovish today."

Eleven of the 13 major sectors rose and the broader, more domestically-focussed small- .NIFSMP100 and mid-caps .NIFMDCP100 gained about 1% each.

The IT index .NIFTYIT rose 0.7%, extending gains for the fourth session in a row, after labour market data eased concerns of recession in the U.S., a key source of revenue for the sector.

The pharma index .NIPHARM added 1.3%, led by a 5% rise in Divi's Laboratories DIVI.NS after Citi initiated coverage of the drugmaker's stock with a "buy" rating.

Torrent Power TOPO.NS jumped 8% after securing two orders from Maharashtra State Electricity Distribution Company for building a total of 2000 MW energy storage capacity.




Reporting by Bharath Rajeswaran in Bengaluru; Editing by Eileen Soreng and Mrigank Dhaniwala

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.